Patents by Inventor Karl Munger

Karl Munger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Inhibiting Tumor Growth
    Publication number: 20120208204
    Abstract: The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells.
    Type: Application
    Filed: June 3, 2010
    Publication date: August 16, 2012
    Applicants: The Brigham and Women's Hospital, Inc., Peresident and Fellows of Harvard College
    Inventors: Amy Baldwin, Dorre Grueneberg, Ed Harlow, Jun Xian, Karl Munger, Karin Hellner, Marcie Glicksman, Ross Stein, Gregory Cuny
  • H3K27me3 and Cancer
    Publication number: 20120202843
    Abstract: Methods of diagnosing and monitoring cancers and precancerous lesions associated with human papillomavirus (HPV), by detecting abnormal levels of lysine (K)-specific demethylase 6A (KDM6A), KDM6B, or trimethylated Histone H3 Lys27 (H3K27me3).
    Type: Application
    Filed: July 14, 2010
    Publication date: August 9, 2012
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Karl Munger, Christopher Crum, Margaret McLaughlin-Drubin
  • Methods and reagents to regulate apoptosis
    Patent number: 6825005
    Abstract: The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in cell cultures, for either making cells more susceptible to apotosis or more resistant to it.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: November 30, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Joshua Syken, Karl Münger
  • Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
    Publication number: 20040097422
    Abstract: Methods are provided for abrogating tripeptidyl peptidase II (TPPII) activity and suppressing c-MYC induced abnormal centriole duplication. Methods of inhibiting TPPII using selective inhibitors such as butabindide provide a preventive or therapeutic strategy to target genomic instability, tumorigenic progression and chemotherapy resistance in tumors with overexpression of c-Myc.
    Type: Application
    Filed: June 13, 2003
    Publication date: May 20, 2004
    Inventors: Karl Munger, Stefan M. Duensing
  • Methods and reagents to regulate apoptosis
    Publication number: 20020086844
    Abstract: The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in cell cultures, for either making cells more susceptible to apotosis or more resistant to it.
    Type: Application
    Filed: July 19, 2001
    Publication date: July 4, 2002
    Inventors: Joshua Syken, Karl Munger
  • Method and kit for evaluating human papillomavirus transformed cells
    Patent number: 5736318
    Abstract: The invention provides methods and kits for determining the extent of interaction and/or inactivation between a cyclin/cyclin-dependent kinase inhibitor and the human papilomavirus E7 oncoprotein and thus for evaluating the proliferative state of a transformed cell. Methods for identifying compounds capable of inhibiting the interaction between a cyclin/cyclin-dependent kinase inhibitor and the human papilomavirus E7 oncoprotein, and for inhibiting growth of a human papillomavirus-associated carcinoma cell are also provided.
    Type: Grant
    Filed: March 17, 1995
    Date of Patent: April 7, 1998
    Assignees: President and Fellows of Harvard College, Harvard University, Office of Technology Transfer
    Inventors: Karl Munger, D. Leanne Jones